Literature DB >> 12860946

Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus.

Satoshi Ishikura1, Keiji Nihei, Atsushi Ohtsu, Narikazu Boku, Shuichi Hironaka, Kiyomi Mera, Manabu Muto, Takashi Ogino, Shigeaki Yoshida.   

Abstract

PURPOSE: To assess the long-term toxicity after definitive chemoradiotherapy (CRT) for squamous cell carcinoma (SCC) of the esophagus. PATIENTS AND METHODS: Patients newly diagnosed with SCC of the esophagus and treated with definitive CRT between 1992 and 1999 in our institution were recruited from our database on the basis of the following criteria: age </= 75 years, performance status (PS; based on the Eastern Cooperative Oncology Group scale) 0 to 2, and clinical tumor-node-metastasis system stage I to IVA. The CRT consisted of two cycles of cisplatin 40 mg/m2 on days 1 and 8, and continuous infusion of fluorouracil 400 mg/m2/d on days 1 to 5 and 8 to 12, repeated every 5 weeks with concurrent radiotherapy of 60 Gy in 30 fractions. For the assessment of toxicity, the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer late radiation morbidity scoring scheme was adopted.
RESULTS: A total of 139 patients were recruited, and their characteristics were as follows: median age, 62 years (range, 38 to 75 years); 121 males and 18 females; 96 patients PS 0, 42 patients PS 1, and one patient PS 2; 15 patients T1, 11 patients T2, 60 patients T3, and 53 patients T4; and 101 patients M0, 38 patients M1a. With a median follow-up of 53 months, the median survival time and 5-year survival rate were 21 months and 29%, respectively. Of 78 patients with complete remission, two patients died as a result of acute myocardial infarction. Grade 2, 3, and 4 late toxicities occurred with the following incidences: pericarditis in eight patients, seven patients, and one patient, respectively; heart failure in zero, zero, and two patients; pleural effusion in seven, eight, and zero patients; and radiation pneumonitis in one patient, three patients, and zero patients, respectively.
CONCLUSION: Definitive CRT for SCC of the esophagus is effective with substantial toxicities. Additional investigation to minimize the normal tissue toxicities is warranted.

Entities:  

Mesh:

Year:  2003        PMID: 12860946     DOI: 10.1200/JCO.2003.03.055

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  124 in total

1.  Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer.

Authors:  Andre Konski; Tianyu Li; Michael Christensen; Jonathan D Cheng; Jian Q Yu; Kevin Crawford; Oleh Haluszka; Jeffrey Tokar; Walter Scott; Neal J Meropol; Steven J Cohen; Alan Maurer; Gary M Freedman
Journal:  Radiother Oncol       Date:  2012-06-07       Impact factor: 6.280

2.  Advantages of salvage photodynamic therapy using talaporfin sodium for local failure after chemoradiotherapy or radiotherapy for esophageal cancer.

Authors:  Tatsunori Minamide; Yusuke Yoda; Keisuke Hori; Kensuke Shinmura; Yasuhiro Oono; Hiroaki Ikematsu; Tomonori Yano
Journal:  Surg Endosc       Date:  2019-05-28       Impact factor: 4.584

Review 3.  Current management of esophageal cancer.

Authors:  Simon Law; John Wong
Journal:  J Gastrointest Surg       Date:  2005-02       Impact factor: 3.452

4.  Promise of definitive chemoradiotherapy for esophageal cancer balanced with late radiation toxicity: an old but new issue.

Authors:  Ichinosuke Hyodo
Journal:  J Gastroenterol       Date:  2006-05       Impact factor: 7.527

5.  Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma.

Authors:  Yosuke Kumekawa; Kazuhiro Kaneko; Hiroaki Ito; Toshinori Kurahashi; Kazuo Konishi; Atsushi Katagiri; Taikan Yamamoto; Meiko Kuwahara; Yutaro Kubota; Takashi Muramoto; Yoshihide Mizutani; Michio Imawari
Journal:  J Gastroenterol       Date:  2006-05       Impact factor: 7.527

6.  Clinical outcomes of radiotherapy for esophageal cancer between 2004 and 2008: the second survey of the Japanese Radiation Oncology Study Group (JROSG).

Authors:  Yasumasa Nishimura; Keiichi Jingu; Satoshi Itasaka; Yoshiharu Negoro; Yuji Murakami; Katsuyuki Karasawa; Gen Kawaguchi; Fumiaki Isohashi; Masao Kobayashi; Yoshiyuki Itoh; Takuro Ariga
Journal:  Int J Clin Oncol       Date:  2015-07-16       Impact factor: 3.402

7.  Predicting the effects of chemoradiotherapy for squamous cell carcinoma of the esophagus by induction chemotherapy response assessed by positron emission tomography: toward PET-response-guided selection of chemoradiotherapy or esophagectomy.

Authors:  Ryu Ishihara; Sachiko Yamamoto; Hiroyasu Iishi; Kengo Nagai; Fumi Matui; Natsuko Kawada; Takashi Ohta; Hiromitsu Kanzaki; Masao Hanafusa; Noboru Hanaoka; Yoji Takeuchi; Koji Higashino; Noriya Uedo; Naotoshi Sugimoto; Yoshifumi Kawaguchi; Kinji Nishiyama; Masaaki Motoori; Masahiko Yano; Takuya Hosoki
Journal:  Int J Clin Oncol       Date:  2011-07-08       Impact factor: 3.402

8.  The evolution of proton beam therapy: Current and future status.

Authors:  Xiufang Tian; Kun Liu; Yong Hou; Jian Cheng; Jiandong Zhang
Journal:  Mol Clin Oncol       Date:  2017-11-14

9.  Hybrid volumetric modulated arc therapy for whole breast irradiation: a dosimetric comparison of different arc designs.

Authors:  Velayudham Ramasubramanian; Karunakaran Balaji; Sitaraman Balaji Subramanian; Krishnamoorthi Sathiya; Moorthi Thirunavukarasu; Chandrasekaran Anu Radha
Journal:  Radiol Med       Date:  2019-01-30       Impact factor: 3.469

10.  Bayesian regression analyses of radiation modality effects on pericardial and pleural effusion and survival in esophageal cancer.

Authors:  Liru He; Andrew Chapple; Zhongxing Liao; Ritsuko Komaki; Peter F Thall; Steven H Lin
Journal:  Radiother Oncol       Date:  2016-08-22       Impact factor: 6.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.